Adocia

Adocia is a legitimate, publicly traded French biopharmaceutical company (Euronext: ADOC) established in 2005 with verified team size (~75) and significant intellectual property (BioChaperone technology). The project addresses a high-utility medical need (diabetes/obesity) with clinical-stage assets (M1Pram, BioChaperone Lispro). However, the submission quality is poor, containing demonstrably false claims ('most people have used my product', audience 'everyone') and confusing market cap with revenue. While the entity itself demonstrates strong 'Real-World Utility' and 'Technical Innovation' typical of a mature biotech, the 'Evidence of Traction' and 'Audience Reach' scores are penalized by the inaccurate submission details, resulting in a score that reflects a solid company presented poorly.